This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prevention of discontinuation syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Prevention
    • Tapering after successful treatment
      • Recommendations on taper length vary
        • has been suggested that antidepressants administered for 8 weeks or more should, wherever possible, be reduced over a 4-week period
        • NICE suggest that
          • normally, gradually reduce the dose over 4 weeks (this is not necessary with fluoxetine). Reduce the dose over longer periods for drugs with a shorter half-life (for example, paroxetine and venlafaxine)

      • routine tapering is probably unnecessary when antidepressants have been prescribed for less than 4 weeks, as discontinuation symptoms are unlikely to occur with such a short duration of treatment (2)
      • an abruption of an antidepressant is justified if a patient has developed serious side effects believed to be due to the antidepressant, there is a medical emergency warranting stopping the antidepressant or the antidepressant has induced mania (2)

    • Tapering and antidepressant switching
      • data imply that if tapering SSRIs and venlafaxine is beneficial in reducing discontinuation symptoms, then it needs to continue for more than 14 days for most patients.
      • a start-taper switch refers to starting the new antidepressant and simultaneously gradually tapering the previous one
        • whether an abrupt switch or start-taper switch is chosen partly depends on the likelihood of discontinuation symptoms occurring, which in turn depends on the pharmacological similarity between the two antidepressants
      • using a washout period (no antidepressant prescribed)
        • is essential when switching to and from MAOIs because of the risk of drug interactions that can lead to serotonin syndrome
        • a washout should also be considered when switching from fluoxetine to a TCA, as the long-half life of fluoxetine, plus its ability to inhibit cytochrome P450 enzymes, could result in elevation of plasma TCA levels, leading to adverse effects (2)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.